In situ carcinoma
disease diseaseOn this page
Also known as carcinoma in situcarcinoma, in situ, malignantCISepithelial tumor, in situ, malignantintraepithelial carcinomanon-invasive carcinomastage 0 disease
Summary
In situ carcinoma (MONDO:0004647) is a cancer (an umbrella term covering 21 Mondo subtypes) and 30 clinical trials. Top therapeutic interventions include hydroxyzine, loperamide, and prochlorperazine. A subtype of carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 21 Mondo subtypes
- Clinical trials: 30
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | in situ carcinoma |
| Mondo ID | MONDO:0004647 |
| MeSH | D002278 |
| DOID | DOID:8719 |
| NCIT | C2917 |
| SNOMED CT | 109355002 |
| UMLS | C0007099 |
| MedGen | 763 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma in situ · carcinoma, in situ, malignant · CIS · epithelial tumor, in situ, malignant · intraepithelial carcinoma · non-invasive carcinoma · stage 0 disease
Disease family
This is a subtype of carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma
Related subtypes (48): retroperitoneum carcinoma, head and neck carcinoma, peritoneal carcinoma, neuroendocrine carcinoma, laryngeal carcinoma, bone carcinoma, carcinoma ex pleomorphic adenoma, scrotal carcinoma, skin carcinoma, malignant myoepithelioma, trachea carcinoma, epithelial-myoepithelial carcinoma, lipid-rich carcinoma, comedocarcinoma, adenocarcinoma, urinary bladder carcinoma, breast carcinoma, squamous cell carcinoma, lung carcinoma, prostate carcinoma, renal carcinoma, uterine carcinoma, vulvar carcinoma, large cell carcinoma, undifferentiated carcinoma, basaloid carcinoma, cribriform carcinoma, digestive system carcinoma, fallopian tube carcinoma, penile carcinoma, sarcomatoid carcinoma, thymic carcinoma, transitional cell carcinoma, ureter carcinoma, papillary carcinoma, Krebs 2 carcinoma, thyroid gland carcinoma, vaginal carcinoma, choroid plexus carcinoma, malignant epithelial tumor of ovary, mucin-producing carcinoma, basal cell carcinoma, carcinoma of urethra, combined carcinoid and adenocarcinoma, secondary carcinoma, invasive carcinoma, glycogen-rich carcinoma, lymph node carcinoma
Subtypes (21): oral cavity carcinoma in situ, pharynx carcinoma in situ, gall bladder carcinoma in situ, adenocarcinoma in situ, nasal cavity carcinoma in situ, skin carcinoma in situ, breast carcinoma in situ, eye carcinoma in situ, lung carcinoma in situ, squamous carcinoma in situ, larynx carcinoma in situ, intestine carcinoma in situ, bladder carcinoma in situ, esophagus carcinoma in situ, uterus carcinoma in situ, liver carcinoma in situ, stomach carcinoma in situ, kidney carcinoma in situ, grade III prostatic intraepithelial neoplasia, carcinoma in situ of ureter, carcinoma in situ of urethra
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
2 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Mitomycin | Approved (phase 3) |
| Valrubicin | Approved (phase 3) |
3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Imiquimod | Phase 2 |
| Megestrol Acetate | Phase 2 |
| Pembrolizumab | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 30.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE1 | 5 |
| PHASE3 | 3 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06390111 | PHASE4 | WITHDRAWN | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. |
| NCT03223753 | PHASE3 | ACTIVE_NOT_RECRUITING | Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer |
| NCT01200992 | PHASE3 | TERMINATED | Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer |
| NCT01310803 | PHASE3 | TERMINATED | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder |
| NCT01316874 | PHASE2/PHASE3 | COMPLETED | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) |
| NCT01438112 | PHASE2/PHASE3 | TERMINATED | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer |
| NCT06833073 | PHASE2 | RECRUITING | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) |
| NCT07322263 | PHASE2 | RECRUITING | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC |
| NCT01731652 | PHASE2 | COMPLETED | Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer |
| NCT02858310 | PHASE1/PHASE2 | COMPLETED | E7 TCR T Cells for Human Papillomavirus-Associated Cancers |
| NCT06022029 | PHASE1 | RECRUITING | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. |
| NCT01236443 | PHASE1 | COMPLETED | Study of Photodynamic Therapy (PDT) Using HPPH in Barrett’s Esophagus |
| NCT01238042 | PHASE1 | COMPLETED | Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett’s Esophagus |
| NCT02698293 | PHASE1 | WITHDRAWN | PDT Plus Vitamin D3 for Anal Dysplasia |
| NCT05014139 | PHASE1 | TERMINATED | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) |
| NCT03182959 | EARLY_PHASE1 | COMPLETED | Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer |
| NCT02402244 | Not specified | RECRUITING | Project: Every Child for Younger Patients With Cancer |
| NCT05463796 | Not specified | RECRUITING | InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer |
| NCT06744140 | Not specified | ACTIVE_NOT_RECRUITING | Role of MRI Breast in Detection of Ductal Carcinoma in Situ |
| NCT01052740 | Not specified | COMPLETED | X-Ray Mammography Standard of Care Protocol |
| NCT01314664 | Not specified | TERMINATED | A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC) |
| NCT01901991 | Not specified | COMPLETED | Localization of Nonpalpable Breast Lesions |
| NCT02039388 | Not specified | COMPLETED | Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma |
| NCT02217358 | Not specified | COMPLETED | Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions |
| NCT03075098 | Not specified | UNKNOWN | Colposcopy in Detection of Oral Epithelial Dysplasia |
| NCT03268993 | Not specified | COMPLETED | Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer |
| NCT03808818 | Not specified | COMPLETED | Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices |
| NCT04312737 | Not specified | COMPLETED | Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus |
| NCT04823871 | Not specified | COMPLETED | Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing |
| NCT06056843 | Not specified | COMPLETED | Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| HYDROXYZINE | 4 | 3 |
| LOPERAMIDE | 4 | 3 |
| PROCHLORPERAZINE | 4 | 3 |
| AMINOLEVULINIC ACID HYDROCHLORIDE | 4 | 1 |
| ATROPINE SULFATE | 4 | 1 |
| CODEINE SULFATE | 4 | 1 |
| DIPHENHYDRAMINE HYDROCHLORIDE | 4 | 1 |
| DIPHENOXYLATE HYDROCHLORIDE | 4 | 1 |
| DROPERIDOL | 4 | 1 |
| ENFORTUMAB VEDOTIN | 4 | 1 |
| GRANISETRON | 4 | 1 |
| IMIQUIMOD | 4 | 1 |
| INDOMETHACIN | 4 | 1 |
| MEPERIDINE | 4 | 1 |
| MITOMYCIN | 4 | 1 |
| VALRUBICIN | 4 | 1 |
| NADOFARAGENE FIRADENOVEC | 3 | 1 |
| HPPH | 2 | 2 |
| INTISMERAN AUTOGENE | 2 | 1 |
| CHEMBL4071382 | 0 | 1 |
| CHEMBL5175144 | 0 | 1 |
| CHEMBL284671 | 0 | 1 |
| CHEMBL399538 | 0 | 1 |